Chisale Master R O, Sinyiza Frank Watson, Kaseka Paul Uchizi, Chimbatata Chikondi Sharon, Mbakaya Balwani Chingatichifwe, Wu Tsung-Shu Joseph, Nyambalo Billy Wilson, Chauma-Mwale Annie, Chilima Ben, Yu Kwong-Leung Joseph, Kayira Alfred Bornwell
Faculty of Sciences, Technology and Innovations, Biological Sciences, Mzuzu University, P/Bag 201 Luwinga, Mzuzu, Malawi.
Research Department, Luke International, Mzuzu P.O. Box 1088, Malawi.
Vaccines (Basel). 2023 Jun 30;11(7):1185. doi: 10.3390/vaccines11071185.
As the fight against the COVID-19 pandemic continues, reports indicate that the global vaccination rate is still far below the target. Understanding the levels of reinfection may help refocus and inform policymakers on vaccination. This retrospective study in Malawi included individuals and patients who tested for COVID-19 infections via reverse transcriptase polymerase chain reaction (rt-PCR) from the data at the Public Health Institute of Malawi (PHIM). We included all data in the national line list from April 2020 to March 2022. Upon review of 47,032 records, 45,486 were included with a reported 82 (0.18) reinfection representing a rate of 0.55 (95% CI: 0.44-0.68) per 100,000 person-days of follow-up. Most reinfections occurred in the first 90 to 200 days following the initial infection, and the median time to reinfection was 175 days (IQR: 150-314), with a range of 90-563 days. The risk of reinfection was highest in the immediate 3 to 6 months following the initial infection and declined substantially after that, and age demonstrated a significant association with reinfection. Estimating the burden of SARS-CoV-2 reinfections, a specific endurance of the immunity naturally gained, and the role played by risk factors in reinfections is relevant for identifying strategies to prioritise vaccination.
随着抗击新冠疫情的斗争仍在继续,报告显示全球疫苗接种率仍远低于目标。了解再感染水平可能有助于重新聚焦并为政策制定者提供疫苗接种方面的信息。这项在马拉维开展的回顾性研究纳入了通过逆转录聚合酶链反应(rt-PCR)检测新冠病毒感染情况的个人和患者,数据来自马拉维公共卫生研究所(PHIM)。我们纳入了2020年4月至2022年3月国家病例清单中的所有数据。在审查47032条记录后,纳入了45486条记录,其中报告有82例(0.18%)再感染,即每10万人日随访的再感染率为0.55(95%可信区间:0.44 - 0.68)。大多数再感染发生在初次感染后的前90至200天,再感染的中位时间为175天(四分位间距:150 - 314),范围为90 - 563天。再感染风险在初次感染后的3至6个月内最高,之后大幅下降,且年龄与再感染存在显著关联。估计新冠病毒再感染的负担、自然获得的免疫力的具体持久性以及风险因素在再感染中所起的作用,对于确定优先接种疫苗的策略具有重要意义。